Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 4 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Metabolic syndrome implicated in hidradenitis suppurativa

06 Jul 2019

Hidradenitis suppurativa (HS) carries about a twofold increased likelihood of having metabolic syndrome, according to the results of a meta-analysis.

Researchers searched multiple online databases for studies comparing patients with HS vs non-HS controls. All studies must have included either the number of patients with metabolic syndrome in each group or the magnitude of association between HS and metabolic syndrome.

The meta-analysis included six case–control studies, all of which had moderate level of evidence, with total scores on the Newcastle-Ottawa scale ranging between 6 and 7 out of 9.

Pooled data revealed metabolic syndrome to be significantly more common in the HS group than in the control group (odds ratio [OR], 1.95, 95 percent CI, 1.31–2.89; p=0.001; I2, 81 percent). The association between HS and metabolic syndrome persisted even after controlling for age, sex, other cardiovascular risk factors and comorbidities (OR, 2.19, 1.70–2.81; p<0.00001; I2, 32 percent).

While it remains to be established whether there exists a causal relationship—whether the chronic inflammatory nature of HS can trigger development of metabolic syndrome or whether associated features of metabolic syndrome predispose patients to develop HS—the researchers postulated that metabolic syndrome-related obesity may predispose to HS via follicular occlusion and the significantly higher amount of adipose cells, which produce inflammatory cytokines.

Nevertheless, the researchers stressed that clinicians managing patients with HS should be aware of the condition’s potential association with metabolic syndrome.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 4 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 06 Dec 2019
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).